BPC-157
The recovery peptide people ask about most, prescribed through a clinician-led program with baseline labs, a licensed U.S. pharmacy and a published monthly price.
- Studied for soft-tissue repair and recovery from training
- Explored for the gut lining, where much of the research is focused
- Used to support a plan built on training, sleep and protein
Individual results vary. Your clinician agrees clear goals with you before you start and reviews them at every follow-up.
- Live visit with a licensed clinician
- If prescribed, medication is included in the price and delivered to your home
- Subscription, cancel anytime
Indicative price · confirmed after eligibility · prescription treatment
What BPC-157 is
BPC-157 is a synthetic chain of fifteen amino acids, based on a sequence found in a protein in human gastric juice. That parent protein was named body protection compound, which is where the initials come from.
It has become one of the most talked-about peptides among people who train hard or notice they recover more slowly than they used to, and the research interest is real: a large body of work explores its role in tendon, ligament, muscle and gut-lining repair. What the human studies show sets out that research in detail.
At ACT 2, BPC-157 is prescribed by a licensed clinician after an assessment and baseline labs, and dispensed by a licensed U.S. compounding pharmacy. You see the monthly price before you book, there is no membership fee, and your clinician follows up and adjusts the plan with you.
BPC-157 is a synthetic peptide based on a sequence identified in human gastric juice; the name stands for body protection compound. It is studied for its role in soft-tissue repair and in the gut lining, and it is one of the most requested peptides among active adults. It is not FDA-approved; it is prepared by a licensed compounding pharmacy under an individual prescription, and it is not equivalent to or interchangeable with any branded medication.
How it works here
Every plan follows one path. Each step feeds the next. See the Peptide Therapy approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
Why people choose BPC-157
Most people come to BPC-157 with a specific goal. Here is how the common ones line up with what the research looks at.
Whatever the goal, BPC-157 works best as part of a plan: the right loading, enough sleep and protein, and a clinician tracking how you respond.
How BPC-157 is thought to work
Preclinical studies explore how BPC-157 interacts with the processes tissue relies on to rebuild, including the formation of new blood vessels and the movement of repair cells into an injured area. That breadth is why it is studied across so many tissue types.
Much of that work comes from one research group and its collaborators, and the field is now looking to independent human trials to build on it. What the human studies show takes the research apart study by study.
BPC-157 and the gut
The digestive tract is where BPC-157 was first described and where much of its research sits: models of stomach and intestinal lining injury, healing of surgical joins, and work on intestinal barrier function, the area behind much of the popular interest in gut-lining support.
BPC-157 was developed as a drug candidate for a digestive condition in the late 1990s and 2000s and reached early-phase human studies without going on to approval. At ACT 2 it is considered as gut-lining support, not as a treatment for any digestive disease, and a gut complaint that has not been worked up is assessed first. BPC-157 and gut health covers it in full.
What the program includes
Every BPC-157 prescription at ACT 2 comes with the same clinical structure:
Clinician-led assessment and prescription. A licensed clinician reviews your history, goals and current medications, and prescribes only when it is appropriate for you.
A licensed U.S. compounding pharmacy. Your prescription is prepared individually for you by a licensed U.S. compounding pharmacy.
Baseline labs and monitoring. A Comprehensive Lab Panel before you start, and the relevant markers rechecked as you go.
A published monthly price. What you pay is on the pricing page before you book, with no hidden consult charge.
Follow-up and adjustment. Your clinician reviews progress against the goals you agreed at the start and adjusts the plan, including when to pause or stop.
No membership fee. There is no fee to be assessed, and you pay for treatment only if it is prescribed and you choose to go ahead.
How it works at ACT 2
A compounded preparation, dispensed by a licensed pharmacy on an individual prescription. How it is taken, and for how long, is set by the prescribing clinician after a review. We do not publish dosing information for any medication — that is a clinical decision made for you individually.
Who it's for
Adults over 45 who train, work physically or are recovering from a soft-tissue strain, and want a clinician to look at their recovery properly. It suits people who like a plan with baseline labs, clear goals and regular check-ins. If you compete in a drug-tested sport, or have a digestive complaint that has not been worked up, raise it at your assessment so your clinician can point you to the right next step. See peptide therapy.
How to get started
Book your BPC-157 visit. A licensed clinician reviews your history, your goals and what is getting in the way of your recovery.
Labs first. A Comprehensive Lab Panel gives your clinician a baseline, and sometimes it points to something worth addressing alongside or instead of a peptide.
A clear goal and a review date. You agree what you are aiming for before you start, so every follow-up has something concrete to measure against.
Single peptide or stack. BPC-157 on its own is the simplest option to evaluate. If you want more than one mechanism covered, ask about the Wolverine Stack or the Repair & Recovery Stack.
Tested athletes. BPC-157 is on the World Anti-Doping Agency's prohibited list, so raise it at your assessment if you compete in a tested sport. For athletes covers recovery more broadly.
The peptide therapy hub explains where these fit. Pricing is on the pricing page; licensing on states we serve.
Clinicians who focus on longevity
Your visit is with a licensed clinician in your state. These are the members of the medical team whose practice centers on longevity; who you see depends on your state and availability.
Medical services are provided by licensed clinicians practicing through an independent professional entity.
Often considered alongside
Wolverine Stack
CompoundedBPC-157 and TB-500 together: two complementary recovery peptides in one clinician-led program, with labs, follow-up and a published monthly price.
View treatmentRepair & Recovery Stack
CompoundedThree peptides in one program: two studied for tissue repair, one for the inflammation around it, prescribed and followed by a clinician.
View treatmentSermorelin ODT
CompoundedThe needle-free route to sermorelin — offered honestly, including what we can't tell you about it.
View treatmentComprehensive Lab Panel
A comprehensive blood panel establishing your baseline across key health markers.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
BPC-157, question by question
The specific questions people bring to this treatment, each answered on its own page and reviewed the same way this one is.
BPC-157 Evidence: What the Human Studies Actually Show
Almost all BPC-157 research is in rodents. The human trials are few, small and mostly old. What the record actually contains, and what it does not.
ReadBPC-157 and the FDA: Where Things Actually Stand
BPC-157 is not FDA-approved. Its status changed twice in 2026 and is still unsettled. What the April removal and the July committee vote actually did.
ReadBPC-157 and Gut Health: The Part with the Most Research Behind It
The gut is where BPC-157 research started and where it is strongest. It is also still preclinical, with no approved indication. An honest look.
Read
What the research shows
BPC-157 has a large preclinical literature, concentrated in tissue-repair and gut models, and limited human data; long-term safety in people has not been studied. It is not FDA-approved for any use. On regulation: in April 2026 the FDA removed twelve peptide substances, BPC-157 among them, from Category 2 of its interim 503A bulk substances list after the nominations were withdrawn. That was not a safety finding, and it did not by itself authorize compounding. In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for the 503A Bulks List. Committee votes are advisory: formal addition to the list requires notice-and-comment rulemaking, which had not completed as of September 2026. Where things stand with the FDA has the detail.
References
Government and professional-society sources consulted for this page.
- FDA Briefing Document for BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 — U.S. Food and Drug Administration (2026)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food and Drug Administration
- BPC-157: Experimental Peptide Creates Risk for Athletes — U.S. Anti-Doping Agency
Frequently asked questions
No. BPC-157 is not FDA-approved for any use. It is prepared by a licensed compounding pharmacy under an individual prescription, after a clinician assessment. The regulatory position explains where the 2026 FDA process stands.
Mostly preclinical: a large animal literature and limited human data. What the human evidence shows sets out the studies in detail.
It is studied for gut-lining support, which is where much of the preclinical research sits. It is not a treatment for any digestive disease, and a gut complaint that has not been worked up is assessed first. See BPC-157 and gut health.
Your prescribing clinician decides how it is taken and for how long, based on your assessment. We do not publish dosing; it is set for you individually.
No one can promise that. BPC-157 is studied for tissue repair and used to support recovery alongside what rebuilds tissue: progressive loading, sleep, protein and time. Your clinician helps you set a realistic goal and tracks it with you.
Yes. BPC-157 is on the World Anti-Doping Agency's prohibited list as a non-approved substance. If you compete in a tested sport, raise it at your assessment before starting; a prescription is not an exemption.
The short-term human data that exists has not shown a signal of harm, but it is limited, and long-term safety in people has not been studied. That is why your history and medications are reviewed first and you are followed up while you are on it.
Much of it is labeled for research use only, which means no one has verified its identity, purity or content. Through ACT 2, BPC-157 is prescribed for you after an assessment and prepared by a licensed U.S. compounding pharmacy.
That is what follow-up is for. Your clinician reviews your progress against the goal you set together and adjusts the plan, including changing course or stopping, so you are never left guessing.
See if BPC-157 fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.